Glutathione (Reduced L-Glutathione)

Glutathione directly scavenges hydrogen peroxide, lipid peroxides, and peroxynitrite, and recycles oxidised vitamin C and E back to active forms. Evidence for its biological role is very strong; evidence that oral supplementation meaningfully raises tissue levels is moderate, best supported for liposomal and sublingual forms in trials showing increased red blood cell and lymphocyte glutathione after 1–6 months.

Glutathione conjugates heavy metals, drug metabolites, and environmental toxins in phase II detoxification, making them water-soluble for excretion. Intravenous and oral glutathione, and its precursor NAC, are used clinically for paracetamol (acetaminophen) overdose and in fatty liver disease. Evidence is strong for the mechanism and for NAC; moderate for oral glutathione in NAFLD where small trials showed reduced ALT.

Lymphocytes and natural killer cells require adequate glutathione to proliferate and mount an effective response; depletion impairs T-cell activity. A 6-month randomised trial found oral glutathione increased NK cell cytotoxicity roughly twofold at 1000 mg daily. Evidence is preliminary but mechanistically plausible.

Glutathione inhibits tyrosinase and shifts melanin synthesis from darker eumelanin toward lighter pheomelanin. Several randomised trials of oral and topical glutathione report modest reductions in melanin index and hyperpigmentation over 4–12 weeks. Effects are real but small, reversible on discontinuation, and unregulated intravenous use for skin whitening has caused serious harm.

Glutathione levels decline with age and in most chronic diseases; restoring it in older adults (using glycine plus NAC, the GlyNAC combination) improved mitochondrial function, insulin sensitivity, inflammation markers, and walking speed in small controlled trials. Evidence for precursor supplementation is emerging and encouraging; direct glutathione data for these outcomes is limited.

Take on an empty stomach, ideally 20–30 minutes before breakfast or at bedtime, to limit degradation by digestive proteases and competition from dietary amino acids. Sublingual forms should be held under the tongue for 60–90 seconds. If splitting a dose, morning and evening on an empty stomach works well.

Best absorbed away from food — at least 30 minutes before or 2 hours after meals. It does not require fat for absorption, though liposomal formulations are already lipid-encapsulated. Avoid taking with high-protein meals, which compete for peptide transporters.

Common oral doses are 250–1000 mg daily; 500 mg daily of liposomal or setria-type reduced glutathione is the most studied range. Skin-brightening trials used 250–500 mg daily for 4–12 weeks. Precursor strategies (NAC 600–1200 mg plus glycine 100 mg/kg) may raise levels more reliably than glutathione itself. Cycle or reassess after 3–6 months rather than taking indefinitely at high dose.

Liposomal glutathione, sublingual tablets, or S-acetyl-L-glutathione are preferred, as standard reduced glutathione capsules are largely broken down in the gut. Avoid oxidised (GSSG) forms unless specifically studied for topical use. Intravenous glutathione should only be given under medical supervision — never for cosmetic whitening.

May trigger bronchospasm in asthmatics, particularly inhaled forms and in people sensitive to sulphites. Theoretically may reduce the efficacy of platinum-based chemotherapy and radiotherapy, which rely on oxidative damage — do not use during cancer treatment without oncologist approval. People with cystinuria, and those on nitrates or immunosuppressants, should seek medical advice first.

Small Japanese trials of oral glutathione at 300 mg daily for four months reduced ALT and liver fat markers in NAFLD patients. The rationale is strong given glutathione depletion in hepatic steatosis, but studies were uncontrolled or small, so evidence is preliminary.

Substantia nigra glutathione is markedly depleted in Parkinson's disease, and early intravenous and intranasal trials suggested symptomatic improvement. However, placebo-controlled trials of intranasal glutathione showed benefit no greater than placebo. Evidence currently does not support it as a treatment, though it remains an active research area.

Airway glutathione is depleted in COPD, cystic fibrosis, and chronic smokers. Nebulised glutathione and oral NAC have shown reduced exacerbations and improved mucus clearance in some trials. Evidence is stronger for NAC than for glutathione itself, and nebulised glutathione can trigger bronchospasm in sulphite-sensitive asthmatics.

Glutathione deficiency correlates with poor glycaemic control and increased oxidative damage in diabetes. GlyNAC (glycine plus N-acetylcysteine) trials in older adults and diabetics showed improved insulin sensitivity and reduced oxidative stress over 12–24 weeks. Evidence is early-stage but consistent.

Oral glutathione 250–500 mg daily and topical oxidised glutathione have shown modest lightening of melasma and UV-induced pigmentation in randomised trials of Asian populations. Effects are mild and require continued use. Best combined with sun protection and topical agents; injectable use for cosmetic whitening is not approved and carries real risk.

NAC supplies cysteine, the rate-limiting amino acid for glutathione synthesis, and reliably raises intracellular glutathione — often more effectively and cheaply than oral glutathione itself. Combining them addresses both direct supply and endogenous production. This is the best-evidenced glutathione-raising strategy. View N-acetylcysteine (NAC) guide →

Glycine is the second most limiting substrate for glutathione synthesis, and its deficiency is common in older adults. The GlyNAC combination (glycine plus NAC) restored glutathione to youthful levels and improved multiple ageing biomarkers in controlled trials. Strong mechanistic and growing clinical support. View Glycine guide →

Vitamin C spares glutathione by handling oxidative load in the aqueous phase, and glutathione in turn regenerates oxidised vitamin C. High-dose vitamin C has been shown to raise red blood cell glutathione levels. Well-established recycling synergy. View Vitamin C guide →

Alpha-lipoic acid regenerates glutathione, vitamin C, and vitamin E, and upregulates the enzymes of glutathione synthesis via Nrf2 signalling. It is both water- and fat-soluble, extending antioxidant coverage across cell compartments. Good mechanistic evidence with supportive human data in diabetic neuropathy. View Alpha-lipoic acid guide →

Selenium is an obligatory cofactor for glutathione peroxidase, the enzyme that uses glutathione to detoxify peroxides. Without adequate selenium, glutathione cannot perform much of its antioxidant work. Strong biochemical evidence; keep intake near 100–200 mcg daily as excess selenium is toxic. View Selenium guide →

Prescription NAC is the standard antidote for paracetamol overdose precisely because it replenishes hepatic glutathione, the same pool oral glutathione aims to support. The shared mechanism is well documented and mechanistically identical at the level of hepatic detoxification, though only IV/oral NAC has proven emergency efficacy.

Silymarin, used clinically in Europe for liver disease, raises hepatic glutathione and stabilises hepatocyte membranes against oxidative injury. The overlap in liver-protective antioxidant mechanism is well supported, though clinical outcome data for both remains modest.

Glutathione shares the tyrosinase-inhibiting, melanogenesis-suppressing mechanism used by depigmenting drugs like hydroquinone, and both reduce melanin index in trials. Glutathione's effect is considerably weaker and slower, so the comparison is mechanistic rather than one of equivalent potency.

Both are used to lower elevated liver enzymes and reduce hepatocellular oxidative stress in cholestatic and fatty liver conditions. The similarity is at the level of hepatoprotective outcome rather than mechanism, and evidence for UDCA is far stronger.